Cervical cancer elimination: leaving no one behind
A future free of cervical cancer is possible. But reaching it depends on making the tools we already have – HPV vaccination, screening and treatment – available to everyone who needs them. Access must not depend on where someone lives or their ability to pay. The scale of the challenge remains substantial. An estimated 604,000 women were diagnosed with cervical cancer worldwide in 2024 , and around 280,000 died from the disease. The highest rates of cervical cancer incidence and mortality are in low- and middle-income countries, reflecting profound inequalities in access to prevention and care. On World Cervical Cancer Elimination Day, FIGO joins the global calls for faster action towards eradicating cervical cancer. HPV vaccination: a powerful, effective and safe medical tool Persistent infection with high-risk types of human papillomavirus (HPV) causes almost all cervical cancers. Vaccination offers a powerful opportunity to prevent the disease before it develops. FIGO’s position statement on HPV vaccination brings together a robust body of evidence demonstrating the effectiveness and safety of this vaccine. Countries with high vaccination coverage have recorded significant reductions in cervical cancer incidence. To build on this progress, we must strengthen HPV vaccination programmes globally as part of efforts to eliminate cervical cancer. Integrating HPV vaccination into national immunisation programmes must be matched by reliable vaccine supplies, sustainable funding and accessible services. Combating misinformation and closing the access gap Clear, trusted information matters. Healthcare professionals have an important role in answering questions and countering misinformation about HPV vaccination. But addressing hesitancy is only the first step, people must also be able to access the vaccine. Practical barriers to vaccination include shortages, poor access and social disadvantage; FIGO’s newly published life-course vaccination collection reinforces this point. For HPV vaccination, the response must combine community engagement with delivery approaches that bring services closer to those who need them. Equitable access must extend beyond vaccination to screening and treatment. These are not separate ambitions: eliminating cervical cancer depends on making all three available to everyone. Together, we can eliminate cervical cancer Cervical cancer elimination is within reach if countries urgently scale up HPV vaccination, high-quality screening and timely treatment, with equity, community trust and political commitment at the centre. OBGYNs have a critical role to play driving this progress, sharing evidence-based information, supporting appropriate vaccination and screening pathways, and advocating for prevention to be embedded in routine healthcare. And national OBGYNs societies can amplify that work by supporting training and pressing for policies that expand equitable access. Ending cervical cancer also demands sustained collaboration between governments, healthcare professionals, civil society and communities to turn shared commitments into increased access to vaccination, screening and treatment. We have the medical tools to eliminate cervical cancer. Our responsibility now is to make sure that their benefits reach everyone. Get involved Be part of this global conversation to improve uptake of cervical cancer screening and treatment, join HIFA today Discover the World Health Organization's World Cervical Cancer Elimination Day campaign and advocacy toolkit Show public support on social media Access FIGO resources on cervical cancer FIGO/IGCS statement on the efficacy of topical treatments for high-risk human papillomavirus in preventing CIN 3+ lesions (free access until 30 November 2026) FIGO position statement on the effectiveness and safety of the HPV vaccine (open access) access) FIGO collection on vaccinating women across the life course (open access) FIGO cancer staging: 2025 update (open access) FIGO webinar: Collaboration for the global elimination of cervical cancer (open access)